Cancer Drug Design and DiscoveryStephen Neidle Elsevier, 28 abr 2011 - 496 páginas The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories |
Índice
METHODOLOGY | 89 |
DRUGS IN THE CLINIC | 155 |
NEW AGENTS | 227 |
THE REALITY OF CANCER DRUGS IN THE CLINIC | 403 |
Glossary | 436 |
| 440 | |
Color Plates | 474 |
Otras ediciones - Ver todo
Términos y frases comunes
acid agents angiogenesis anti-angiogenic anti-tumor activity anticancer antifolate apoptosis assay bevacizumab binding Biochem Biol biological biomarkers BRAF breast cancer c-Kit camptothecin cancer cells cancer drug Cancer Res CDK2 cell cycle cell lines cellular chaperone Chem cisplatin client proteins Clin clinical trials complex compounds Curr cyclin cytotoxic DFG motif DNA repair drug development Drug Discov drug discovery effects efficacy EGFR endothelial enzyme erlotinib Figure function gefitinib geldanamycin gene growth factor heat shock protein HSP90 inhibitors human imatinib induced inhibition interactions irinotecan kinase inhibitors ligand mechanism metastatic mice models molecular molecules mutations novel oncogenic Oncol oncology PARP pathway pemetrexed percent pharmacokinetic Pharmacol Phase I study Phase II trial phosphorylation potential preclinical protein kinase radicicol raltitrexed receptor resistance response screening selective signaling small-molecule sorafenib structure synthesis target temozolomide therapeutic therapy tion tissues topoisomerase topotecan tors toxicity trastuzumab treatment tumor tumor cells tyrosine kinase VEGF vitro vivo xenografts